CJC-1295 DAC: Side Effects

Safety Profile Overview#

CJC-1295 DAC has demonstrated a generally favorable safety profile in the limited clinical trial data available. The Phase 1 and Phase 2 studies conducted in healthy adults, growth hormone-deficient subjects, and elderly volunteers reported no serious adverse events attributable to the compound. The most common adverse events were local injection site reactions, which were mild and self-limiting.

However, the clinical safety database for CJC-1295 DAC is limited in both the number of subjects studied and the duration of exposure (maximum 8 weeks). The long-term safety implications of sustained GH and IGF-1 elevation, which would be expected with chronic use, have not been evaluated in clinical trials.

Clinical Trial Safety Data#

Teichman et al. (2006)#

In the pivotal pharmacokinetic and pharmacodynamic study, CJC-1295 DAC was well tolerated across all dose levels studied (30 to 120 mcg/kg). Injection site reactions, including mild erythema, induration, and discomfort, were the most frequently reported adverse events. These reactions were transient and did not lead to study discontinuation.

Other reported adverse events included transient flushing, headache, dizziness, and mild gastrointestinal symptoms. All adverse events were classified as mild to moderate in severity. No dose-limiting toxicities were identified at doses up to 120 mcg/kg.

Importantly, no significant changes in hematological parameters, hepatic function, renal function, or cardiovascular parameters were observed during the study period. Glucose and insulin levels were monitored but did not show clinically significant changes at the doses and durations studied.

Ionescu and Frohman (2006)#

The study evaluating CJC-1295 in healthy, GH-deficient, and elderly subjects similarly reported no serious adverse events. The safety profile was consistent across the different populations studied, with injection site reactions remaining the most common adverse event.

Theoretical Risks of Sustained GH/IGF-1 Elevation#

While the short-term clinical safety data are reassuring, the sustained elevation of GH and IGF-1 produced by CJC-1295 DAC raises theoretical safety concerns that are well-documented from the GH replacement therapy literature.

Insulin Resistance and Glucose Metabolism#

Growth hormone is a counter-regulatory hormone that opposes the action of insulin. Chronic GH elevation can lead to insulin resistance, impaired glucose tolerance, and in susceptible individuals, diabetes mellitus. This effect is dose-dependent and is more likely with sustained, non-pulsatile GH elevation. The pulsatile GH secretion pattern preserved by CJC-1295 DAC may mitigate this risk compared to continuous GH infusion, but the clinical significance of this difference for long-term metabolic safety has not been established.

Fluid Retention#

GH stimulates sodium and water retention through renal and extrarenal mechanisms. In the GH replacement therapy literature, edema and carpal tunnel syndrome are well-documented side effects. With CJC-1295 DAC, mild fluid retention would be expected with sustained use, particularly at higher doses.

Musculoskeletal Effects#

Chronic GH elevation is associated with joint pain (arthralgia), muscle pain (myalgia), and carpal tunnel syndrome. These effects are mediated through the growth-promoting actions of GH and IGF-1 on connective tissues and are common dose-dependent side effects of GH replacement therapy.

Cancer Risk#

The relationship between GH/IGF-1 levels and cancer risk is an area of active investigation. Epidemiological studies have demonstrated associations between higher circulating IGF-1 levels and increased risk of certain cancers, particularly colorectal, prostate, and breast cancer. While a causal relationship has not been definitively established, this association raises concern about long-term use of any compound that chronically elevates IGF-1 levels.

CJC-1295 DAC is contraindicated in individuals with active malignancy or a history of cancer, as elevated GH and IGF-1 could theoretically promote tumor growth or recurrence.

Contraindications#

Based on the pharmacological effects of CJC-1295 DAC and the known risks of GH/IGF-1 elevation, the following contraindications apply:

• Active malignancy or cancer history: GH and IGF-1 have mitogenic properties that could promote tumor growth.
• Uncontrolled diabetes: GH-mediated insulin resistance could worsen glycemic control.
• Active pituitary pathology: Including pituitary tumors, recent pituitary surgery, or pituitary radiation; the effects of exogenous GHRH stimulation on pathological pituitary tissue are unpredictable.
• Pregnancy and breastfeeding: No reproductive toxicology data are available.
• Intracranial hypertension: GH therapy is associated with intracranial hypertension, particularly in pediatric populations.

Drug Interactions#

Growth Hormone Therapy#

CJC-1295 DAC should not be combined with exogenous growth hormone therapy, as this would produce additive elevation of GH and IGF-1 levels with increased risk of dose-dependent adverse effects.

Insulin and Oral Hypoglycemic Agents#

The insulin-antagonistic effects of GH elevation may alter insulin requirements in diabetic patients or increase blood glucose in non-diabetic individuals. Monitoring of glucose levels is recommended, and adjustment of diabetes medications may be necessary.

Glucocorticoids#

Glucocorticoids are known to inhibit GH secretion and may attenuate the pharmacodynamic effects of CJC-1295 DAC. Conversely, the anabolic effects of GH may partially counteract the catabolic effects of glucocorticoids. The net clinical effect of this interaction is complex and not well characterized.

Other GH Secretagogues#

Combination of CJC-1295 DAC with GH-releasing peptides (such as GHRP-6 or ipamorelin) produces synergistic GH release, as GHRH and ghrelin-mimetic peptides act through complementary pathways. While this combination is commonly discussed in research contexts, the safety of combined secretagogue use has not been evaluated in clinical trials.

Related Reading#

• CJC-1295 DAC overview and research guide
• CJC-1295 DAC dosing protocols
• CJC-1295 DAC risks and legal status